S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
NASDAQ:RLMD

Relmada Therapeutics - RLMD Stock Forecast, Price & News

$2.26
-0.06 (-2.59%)
(As of 03/24/2023 02:46 PM ET)
Add
Compare
Today's Range
$2.00
▼
$2.27
50-Day Range
$2.32
▼
$4.76
52-Week Range
$1.81
▼
$38.68
Volume
214,279 shs
Average Volume
282,525 shs
Market Capitalization
$68.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Relmada Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
840.4% Upside
$20.50 Price Target
Short Interest
Healthy
4.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
-0.16mentions of Relmada Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.37) to ($3.83) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

159th out of 989 stocks

Pharmaceutical Preparations Industry

62nd out of 480 stocks

See Top Rated MarketRank™ Stocks Here

RLMD stock logo

About Relmada Therapeutics (NASDAQ:RLMD) Stock

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLMD Stock News Headlines

March 24, 2023 | finance.yahoo.com
Q4 2022 Relmada Therapeutics Inc Earnings Call
March 24, 2023 | finanznachrichten.de
Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 24, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 23, 2023 | finance.yahoo.com
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 22, 2023 | benzinga.com
Preview: Relmada Therapeutics's Earnings
March 22, 2023 | americanbankingnews.com
Relmada Therapeutics (RLMD) Scheduled to Post Earnings on Thursday
March 19, 2023 | americanbankingnews.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $14.00 Consensus Target Price from Brokerages
March 17, 2023 | finance.yahoo.com
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
March 24, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
February 17, 2023 | finance.yahoo.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the company
February 16, 2023 | nasdaq.com
Deep Track Capital Now Owns 9.43% of Relmada Therapeutics (RLMD)
January 23, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Relmada Therapeutics (RLMD)
January 9, 2023 | finance.yahoo.com
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
December 15, 2022 | finance.yahoo.com
Sergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More Shares
December 9, 2022 | msn.com
Looking Into Relmada Therapeutics's Recent Short Interest
December 8, 2022 | marketwatch.com
Relmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMD
December 8, 2022 | marketwatch.com
Relmada Therapeutics Shares Slide Premarket on Study Failure >RLMD
December 8, 2022 | finance.yahoo.com
Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke
December 8, 2022 | finance.yahoo.com
Relmada Therapeutics shares decline 40% on Thursday
November 30, 2022 | seekingalpha.com
Relmada Therapeutics: Trading Below Cash With 2 Clinical Readouts Ahead
November 10, 2022 | finance.yahoo.com
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 3, 2022 | finance.yahoo.com
We Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth Carefully
October 14, 2022 | 247wallst.com
Relmada Shares Plunge More Than 75% After Depression Drug Trial Fails
October 13, 2022 | za.investing.com
Oppenheimer Cautions Against Relmada Therapeutics Trial Optimism
October 13, 2022 | markets.businessinsider.com
Relmada Stock Tumbles To 52-Week Low On Failed Depression Trial
October 13, 2022 | seekingalpha.com
Relmada stock crashes 78% as depression therapy REL-1017 fails phase 3 trial
October 13, 2022 | marketwatch.com
Relmada Therapeutics Shares Plummet on Phase 3 Study Failure >RLMD
See More Headlines
Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLMD Company Calendar

Last Earnings
11/11/2021
Today
3/24/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLMD
CUSIP
N/A
CIK
1553643
Web
www.relmada.com
Phone
(786) 629-1376
Fax
N/A
Employees
10
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+783.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-125,750,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.53%
Return on Assets
-72.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.01
Quick Ratio
9.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.89 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
30,100,000
Free Float
27,240,000
Market Cap
$69.83 million
Optionable
Optionable
Beta
0.15

Social Links


Key Executives

  • Sergio Traversa
    Chief Executive Officer & Director
  • Maged S. ShenoudaMaged S. Shenouda
    Chief Financial Officer
  • Paolo Manfredi
    Chief Scientific Officer
  • Marc L. de Somer
    Senior Vice President-Clinical Development
  • Cedric O'Gorman
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RLMD Stock - Frequently Asked Questions

Should I buy or sell Relmada Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RLMD, but not buy additional shares or sell existing shares.
View RLMD analyst ratings or view top-rated stocks.

What is Relmada Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued 12 month price objectives for Relmada Therapeutics' stock. Their RLMD share price forecasts range from $4.00 to $60.00. On average, they expect the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 783.6% from the stock's current price.
View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts.

How have RLMD shares performed in 2023?

Relmada Therapeutics' stock was trading at $3.49 on January 1st, 2023. Since then, RLMD stock has decreased by 33.5% and is now trading at $2.32.
View the best growth stocks for 2023 here.

When is Relmada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our RLMD earnings forecast.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its earnings results on Thursday, November, 11th. The company reported ($2.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.62) by $0.82.

What ETFs hold Relmada Therapeutics' stock?

ETFs with the largest weight of Relmada Therapeutics (NASDAQ:RLMD) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).Psyk Etf (PSYK).

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD."

Who are Relmada Therapeutics' major shareholders?

Relmada Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Millennium Management LLC (3.53%), Two Sigma Investments LP (1.75%), Morgan Stanley (1.62%), Geode Capital Management LLC (1.62%), Mirae Asset Global Investments Co. Ltd. (0.93%) and Renaissance Technologies LLC (0.72%). Insiders that own company stock include Charles J Casamento, Charles J Casamento, Maged Shenouda, Paul Edward Kelly and Sergio Traversa.
View institutional ownership trends.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $2.32.

How much money does Relmada Therapeutics make?

Relmada Therapeutics (NASDAQ:RLMD) has a market capitalization of $69.83 million. The company earns $-125,750,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis.

How can I contact Relmada Therapeutics?

Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The official website for the company is www.relmada.com. The company can be reached via phone at (786) 629-1376 or via email at mbecker@relmada.com.

This page (NASDAQ:RLMD) was last updated on 3/24/2023 by MarketBeat.com Staff